|
KOBAYASHI Hirohito
Department School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine Position Associate Professor |
|
| Article types | Review article |
| Language | English |
| Peer review | Peer reviewed |
| Presence of invitation | Invited paper |
| Title | γδ T Cell Immunotherapy-A Review. |
| Journal | Formal name：Pharmaceuticals (Basel, Switzerland) Abbreviation：Pharmaceuticals (Basel) ISSN code：14248247/14248247 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 8(1),pp.40-61 |
| Author and coauthor | Kobayashi Hirohito, Tanaka Yoshimasa |
| Publication date | 2015/02 |
| Summary | Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy. |
| DOI | 10.3390/ph8010040 |
| PMID | 25686210 |